Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pimurutamab - Shanghai Henlius Biotech

Next Previous
Drug Profile

Pimurutamab - Shanghai Henlius Biotech

Alternative Names: Cetuximab biobetter - Henlix Biotech; HLX 07; Recombinant humanized anti-EGFR monoclonal antibody - Shanghai Henlius Biotech

Latest Information Update: 16 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Henlius Biotech
  • Developer Shanghai Henlius Biotech; Wuhan Union Hospital
  • Class Antineoplastics; Biobetters; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Rectal cancer; Squamous cell cancer
  • Phase I/II Colorectal cancer; Solid tumours

Most Recent Events

  • 11 Feb 2026 Phase-I/II clinical trials in Colorectal cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in China (IV) (NCT07358585)
  • 06 Jan 2026 Shanghai Henlius Biotech plans to initiate a phase II/III trial for Squamous non-small cell lungs cancer (Combination therapy, Late-stage disease, First-line treatment, Recurrent, Metastatic disease) in China (IV) (NCT07318883)
  • 02 Nov 2025 Efficacy and adverse events data from a phase II trial in Non-small cell lung cancer released by Shanghai Henlius Biotech

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top